Allen Cunningham (L) and Shaharyar Khan (Rivus)

Tak­ing on Big Phar­ma-sized in­di­ca­tions, tiny biotech claims ear­ly win in fat loss. Will it trans­late to di­a­betes, NASH and be­yond?

As Big Phar­ma races to beef up their fran­chis­es in car­diometa­bol­ic dis­eases, a much small­er play­er wants to give them a run for their mon­ey,

And Rivus Phar­ma­ceu­ti­cals, a tiny biotech with on­ly sev­en full-time em­ploy­ees, says it has the pre­lim­i­nary da­ta to sug­gest that its lead drug can play a big role in large in­di­ca­tions like heart fail­ure with pre­served ejec­tion frac­tion, type 2 di­a­betes and non-al­co­holic steato­hep­ati­tis (NASH) — the last be­ing a no­to­ri­ous waste­land for drug de­vel­op­ment ef­forts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.